ANDA Victory for McAndrews Client Accord Healthcare, Inc.
On April 11, 2023, the District Court for the District of Delaware issued its opinion in favor of McAndrews client Accord Healthcare Inc.
Accord filed an abbreviated new drug application (ANDA) for approval to market a generic version of Purdue Pharma’s OxyContin® branded extended release oxycodone hydrochloride tablets.
Purdue Pharma alleged that Accord’s proposed ANDA product would infringe five Purdue patents if marketed. Accord asserted that each of the five patents was invalid. The District Court held a three-day trial in September 2022 and issued its opinion on April 11, 2023 siding with Accord and invalidating all of the asserted claims of the five Purdue patents.